Fasenra® 30 mg solution for injection in pre-filled pen is a significant advancement in the treatment of eosinophilic asthma and eosinophilic granulomatosis. This injectable medication, containing the active ingredient benralizumab, helps to reduce eosinophil levels in the body, leading to improved respiratory health. Understanding its uses, side effects, and precautions is essential for patients considering this treatment.
In this article, we will explore the various aspects of Fasenra®, including its mechanism of action, common side effects, and important safety information to ensure effective use.
What is Fasenra® 30 mg solution for injection?
Fasenra® is a monoclonal antibody designed to target and deplete eosinophils, a type of white blood cell involved in inflammatory processes, particularly in eosinophilic asthma. By reducing eosinophil levels, Fasenra® helps to alleviate airway inflammation, leading to improved breathing and reduced asthma attacks.
This medication is administered through a subcutaneous injection, typically every 4 to 8 weeks, depending on the patient’s condition and healthcare provider’s recommendations. It is crucial to follow the prescribed dosage to achieve the best results.
Moreover, Fasenra® is available in a convenient pre-filled pen, making self-administration easier for patients. This can enhance compliance and ensure that patients receive their treatment as scheduled.
How does Fasenra® work in treating eosinophilic asthma?
Fasenra® works by targeting the IL-5 receptor on eosinophils, effectively reducing their lifespan and preventing their proliferation. This results in lower eosinophil counts in the blood and tissues, leading to decreased inflammation.
The mechanism of action can be summarized as follows:
- Targeted action: Fasenra® specifically binds to the IL-5 receptor.
- Eosinophil depletion: The medication promotes the destruction of eosinophils.
- Inflammation reduction: Lower eosinophil levels lead to reduced respiratory inflammation.
As a result, patients often experience fewer asthma symptoms, improved lung function, and a reduction in the frequency of asthma attacks. This makes Fasenra® an effective option for those with severe eosinophilic asthma.
What are the common side effects of Fasenra®?
While Fasenra® is generally well-tolerated, some patients may experience side effects. Common side effects include:
- Headaches
- Sore throat
- Injection site reactions (redness, swelling)
- Fatigue
These side effects are typically mild to moderate and resolve on their own. However, it’s important for patients to monitor their symptoms and report any persistent or severe reactions to their healthcare provider.
In rare cases, serious allergic reactions can occur. If a patient experiences symptoms such as difficulty breathing, swelling of the face or throat, or rash, they should seek immediate medical attention.
What are the warnings and precautions for Fasenra®?
Before starting treatment with Fasenra®, patients should be aware of certain warnings and precautions:
1. Allergic reactions: Patients with a history of allergies should disclose this information to their healthcare provider.
2. Infections: Fasenra® may increase the risk of infections, so patients should be monitored for signs of infection during treatment.
3. Vaccinations: Patients should consult their healthcare provider regarding vaccinations, as some vaccines may not be recommended during treatment.
Additionally, it is essential to inform healthcare providers of any other medications being taken to avoid potential interactions.
How is Fasenra® administered and stored?
Fasenra® is administered via a subcutaneous injection in the thigh, abdomen, or upper arm. It is crucial to follow the healthcare provider’s instructions regarding the injection technique to ensure proper administration.
For storage:
- Keep Fasenra® in the refrigerator (between 36°F to 46°F or 2°C to 8°C).
- Avoid exposure to light.
- Do not freeze the medication.
- After removal from the refrigerator, Fasenra® can be kept at room temperature for up to 14 days.
Proper storage and handling are vital for maintaining the medication’s effectiveness and safety.
What are the differences between Fasenra® pen and syringe?
Fasenra® is available in two forms: the pre-filled pen and the syringe. Here are the key differences:
- Ease of use: The pre-filled pen is designed for self-administration, making it user-friendly.
- Accuracy: Both forms deliver the same active ingredient, but the pen may offer more precise dosing.
- Comfort: Patients may find the pen easier and less intimidating than a syringe.
Ultimately, the choice between the two forms depends on patient preference and healthcare provider recommendations.
How much does Fasenra® injection cost?
The cost of Fasenra® can vary based on several factors, including:
- Insurance coverage: Patients should check their insurance plan for coverage details.
- Location: Prices may differ by pharmacy or healthcare facility.
- Patient assistance programs: Some manufacturers offer programs to help reduce costs for eligible patients.
It is advisable for patients to discuss costs and available financial assistance options with their healthcare providers.
Frequently asked questions about Fasenra®
What is Fasenra 30 mg used for?
Fasenra® 30 mg solution for injection is primarily used to treat eosinophilic asthma and eosinophilic granulomatosis with polyangiitis (EGPA). By targeting eosinophils, it helps reduce inflammation and improve respiratory function. This can lead to fewer asthma attacks and better overall control of the condition.
What is the difference between Fasenra and Fasenra pen?
The primary difference between Fasenra and Fasenra pen lies in the method of administration. Fasenra pen is a pre-filled device designed for easy self-injection, while the syringe may require a bit more skill for proper administration. Both formulations deliver the same medication and dosage but cater to different patient preferences.
Is Fasenra a chemotherapy drug?
No, Fasenra® is not a chemotherapy drug. It is a targeted biologic therapy used specifically for treating eosinophilic asthma and related conditions. Unlike chemotherapy agents, which target rapidly dividing cells, Fasenra® selectively targets eosinophils to reduce inflammation.
What is the injection of Fasenra pen?
The injection of Fasenra pen refers to the process of administering the medication using the pre-filled device. It is designed for easy use, allowing patients to self-administer the medication subcutaneously. The pen includes a safety mechanism to prevent needle stick injuries and ensures the correct dosage is delivered.